Delthia Ricks

Medical science has long been on the hunt for a deeper understanding of the devastating scarring of the body's organs known as fibrosis, which leads to irrevocable loss of function.

Five years ago, at the outset of the coronavirus pandemic, a phenomenon became abundantly clear: Preschool-age children rarely developed severe cases of COVID-19.

Few autoimmune disorders are more challenging for patients than multiple sclerosis, a progressive condition that can affect vision, impair the ability to walk, cause extreme bouts of neuropathic pain, and tends to strike women at three times the rate of men.

A critical challenge during the early COVID-19 pandemic was determining whether a patient would survive the infection or die from it. And even though a host of lifesaving therapeutics now spares substantially more lives than four years ago, the art of predicting COVID outcomes remains a matter of scientific pursuit.

A critical challenge during the early COVID-19 pandemic was determining whether a patient would survive the infection or die from it.

Infections in the lower urinary tract rarely migrate to the kidneys, but the precise mechanism that the human body employs to keep the twin organs disease-free has remained a medical mystery—until now.

A rare autoimmune condition with a tongue-twister of a name may impact people of Puerto Rican heritage through a newly discovered genetic pathway, a discovery that may ultimately guide genetic counseling and treatment, scientists associated with the discovery say.

In 1982, two Australian physician–scientists discovered a spiral-shaped bacterium whose form not only dictated its function, but its capacity to dwell in the human body's harshest chemical environment would help identify it as the cause of serious afflictions of the stomach, including cancer.

Scientists have identified "immune pathways" during acute coronavirus infection that are associated with the development of long COVID, and while some pathways are the same for men and women, others differ dramatically along a sharp divide between the sexes.

An investigational therapy is demonstrating preclinical promise against non-Hodgkin lymphoma by boosting natural killer cells and efficiently annihilating the malignancy without toxicity to the patient, a team of cancer biologists in France has found.